Navigation Links
NexMed Announces Completion of Patient Enrollment in Two Pivotal,Phase 3 Studies for Anti-Fungal Product

EAST WINDSOR, N.J.--(BUSINESS WIRE)--July 9, 2007 - NexMed, Inc. (NASDAQ: NEXM), a developer of innovative transdermal treatments based on the NexACT(R) drug delivery technology, today announced that Novartis Pharma AG has completed patient enrollment for Phase III clinical trials for NM100060, a topical treatment for onychomycosis (nail fungus). Pursuant to the terms of the licensing agreement with Novartis, NexMed will be entitled to a milestone payment early next year. NexMed entered into an exclusive, worldwide agreement with Novartis in September 2005, under which Novartis assumed all clinical development, regulatory, manufacturing and commercialization responsibilities for NM10060.

NM100060 is a topical application of Lamisil(R) (terbinafine), formulated with terbinafine and the Company's patented NexACT permeation enhancer, which facilitates the delivery of the drug into the nail bed, where the fungus resides.

About NexMed

NexMed, Inc. is an emerging drug developer that is leveraging its proprietary drug technology to develop a significant pipeline of innovative pharmaceutical products to address significant unmet medical needs. The Company is also working with various pharmaceutical companies to explore the incorporation of NexACT(R) into their existing drugs as a means of developing new patient-friendly transdermal products and extending patent lifespans and brand equity. For further information about the Company, go to www.nexmed.com.

Statements under the Private Securities Litigation Reform Act: with the exception of the historical information contained in this release, the matters described herein contain forward-looking statements that involve risk and uncertainties that may individually or mutually impact the matters herein described, including but not limited to its ability to maintain reduced expenditures, enter into partnering agreements, pursue growth opportunities, and/or other factors, some of which are outside the control of the Company.

Contact

NexMed, Inc.
Linda Burns, 609-371-8123, ext: 184
Senior Director Corporate Relations
lburns@nexmed.com
or
Investor Relations:
Rx Communications Group, LLC
Paula Schwartz, 917-322-2216
pschwartz@rxir.com


'"/>




Related medicine technology :

1. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
2. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
4. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
5. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
8. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
9. Protox Announces Positive Clinical Data from Prostate Cancer Study
10. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
11. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2020)... ... August 27, 2020 , ... InfoMC, a leading provider ... of their 2020 System and Organizational Controls (SOC) 1® Type 2 and SOC ... compliance assessment. These achievements reflect their long-standing commitment to privacy, security, and risk ...
(Date:8/27/2020)... , ... August 27, 2020 , ... Bleep LLC, maker ... and sleep apnea patient, is the company’s new spokesperson. , “In my line of ... So, when I found the Bleep DreamPort it was a Bleeping no brainer for ...
(Date:8/27/2020)... ... August 27, 2020 , ... The GHT Companies ... its fundraising initiative for Feeding San Diego with a press conference at ... Companies presents the final check of $5,000.00+ representing an overall donation result exceeding $30,000 ...
Breaking Medicine Technology:
(Date:9/1/2020)... GLENDALE, Calif. (PRWEB) , ... September 01, 2020 ... ... opened a new practice in Glendale. While the office will be ... procedures as breast augmentation, tummy tucks, buttock augmentation (Brazilian butt lift), as well ...
(Date:9/1/2020)... , ... September 01, 2020 , ... ... with specialty fellowship training in aesthetic surgery of the face, breast, and body. ... the only female-owned premier boutique plastic surgery and aesthetic practice in Southwest Florida. ...
(Date:8/31/2020)... SPRINGS, Miss. (PRWEB) , ... August 31, 2020 ... ... Plus (GCPP) recently donated 1,400 N95 face masks to medical first responders across ... has continued to make donations of personal protective equipment (PPE) medical centers ...
(Date:8/31/2020)... ... August 31, 2020 , ... Smile Brands Inc., one ... the United States, today announced the grand opening of another affiliated Bright ... will enjoy convenient hours, a comfortable office, and full-service care at the new ...
(Date:8/31/2020)... ... August 31, 2020 , ... ... both directly with persons with autism and other developmental disabilities, as well as ... intervention, parent education, adolescents with autism, school consultation, and staff development. She joined ...
Breaking Medicine News(10 mins):